EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases
- 113 Downloads
32P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom 32P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.
The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for 32P phosphate therapy.
KeywordsGuidelines Nuclear medicine 32P phosphate Polycythaemia vera Essential thrombocythaemia Radionuclide therapy